TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

Reuters

2025/07/24

TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553789613"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553789613\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553789613?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553789613","market":"fut","top_or_hot":-1,"title":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL2Qlcly:1","article_id":"2553789613","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553789613","pubTimestamp":1753368488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025. TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology  Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02410":"同源康医药-B"},"translate_title":"TYK Medicines Inc.宣布TY-302、TY-2699a和TY-0540的I期临床试验结果被接受在2025年ESMO大会上展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    \n\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}